About DNA-directed RNA polymerase III subunit RPC7-like
DNA-directed RNA polymerase III subunit RPC7-like (POLR3GL) is a protein
from Homo sapiens identified by UniProt accession
Q9BT43, 218 residues long.
MolForge cross-references it against 0 known binders and
62 disease associations.
Target properties
| Protein name | DNA-directed RNA polymerase III subunit RPC7-like |
|---|
| UniProt accession | Q9BT43 |
|---|
| Gene | POLR3GL |
|---|
| Organism | Homo sapiens |
|---|
| Length | 218 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (62)
Diseases linked to this target (Open Targets).
- short stature, oligodontia, dysmorphic facies, and motor delay · score 0.55
- tooth agenesis · score 0.32
- Short stature · score 0.32
- Abnormal facial shape · score 0.32
- hyperostosis · score 0.32
- neutrophil count · score 0.28
- leukocyte count · score 0.21
- endometrial cancer · score 0.18
- neurogenic locus notch homolog protein 2 measurement · score 0.10
- infantile-onset autosomal recessive nonprogressive cerebellar ataxia · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9BT43-F1 | alphafold | PREDICTED | 71.40 | — |
Amino-acid sequence (218 residues)
MASRGGGRGR GRGQLTFNVE AVGIGKGDAL PPPTLQPSPL FPPLEFRPVP LPSGEEGEYV LALKQELRGA MRQLPYFIRP AVPKRDVERY SDKYQMSGPI DNAIDWNPDW RRLPRELKIR VRKLQKERIT ILLPKRPPKT TEDKEETIQK LETLEKKEEE VTSEEDEEKE EEEEKEEEEE EEYDEEEHEE ETDYIMSYFD NGEDFGGDSD DNMDEAIY
Explore DNA-directed RNA polymerase III subunit RPC7-like with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets